You walk into your neighbourhood pharmacy.
You ask for a strip of tablets.
The packaging looks fine. The price feels normal.
But here's the uncomfortable question nobody at the counter is asking:
Did that medicine ever get approved to enter India?
India's drug regulator just admitted — quietly, in an internal advisory — that the answer is increasingly… no.
The Central Drugs Standard Control Organisation has fired off a nationwide advisory.
To every state drug controller.
To every UT.
To every zonal and port office.
The message is blunt:
👉 Tighten the screws. Now.
Unapproved, unlicensed, unregistered drugs are slipping into the country — and ending up on shelves, in clinics, in hospitals, in someone's medicine cabinet.
The advisory names the weak spots with surgical precision:
Basically — every crack in the supply chain a smuggler could squeeze through.
And the context isn't pretty.
India's Northeast has long been a known corridor between Myanmar and Bangladesh. Assam alone has seized drugs worth around ₹26 billion since 2021. Just last month, the NCB busted a ₹115 crore India-Myanmar narco syndicate.
This isn't a paperwork problem. It's a porous-border problem.
The advisory isn't a polite nudge. It's a checklist with teeth.
No link in the chain gets a free pass.
Unapproved doesn't just mean paperwork missing.
It can mean:
India is the pharmacy of the world — exporting medicines to over 200 countries.
The irony? At home, a parallel grey market has been quietly building inside the same supply chain we're so proud of.
A country's drug safety isn't tested in a lab.
It's tested at the last mile — the small-town chemist, the rural clinic, the courier package nobody scans twice.
CDSCO has finally said the quiet part out loud.
Now the real test begins — not in writing the advisory, but in enforcing it before the next strip of unknown pills ends up in someone's hand.
That's all for now!
